| Dr Archie Charles Perry Jr, MD | |
|
2800 E Desert Inn Rd Ste 100, Las Vegas, NV 89121-3609 | |
| (702) 731-1616 | |
| (702) 734-4900 |
| Full Name | Dr Archie Charles Perry Jr |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 26 Years |
| Location | 2800 E Desert Inn Rd Ste 100, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245218510 | NPI | - | NPPES |
| CC6778 | Other | BXBS | |
| 7499443 | Other | AETNA | |
| 1245218510 | Medicaid | NV | |
| P00142405 | Other | R.R. MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | 42033 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Health Home Health | Las vegas, NV | Home health agency |
| Southern Hills Hospital And Medical Center | Las vegas, NV | Hospital |
| Spring Valley Hospital Medical Center | Las vegas, NV | Hospital |
| University Medical Center | Las vegas, NV | Hospital |
| Sunrise Hospital And Medical Center | Las vegas, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Desert Orthopaedic Center Ltd | 6406759661 | 91 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
Forty years ago there were five workers for every retiree. Now there are three. Within a couple of decades, there will be only two workers per retiree. There's no way just two workers will be able or willing to pay enough payroll taxes to keep benefits flowing to every retiree (Robert Reich, 4/11).
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 3 days ago
| Entity Name | Desert Orthopaedic Center Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548235302 PECOS PAC ID: 6406759661 Enrollment ID: O20040127001024 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
Forty years ago there were five workers for every retiree. Now there are three. Within a couple of decades, there will be only two workers per retiree. There's no way just two workers will be able or willing to pay enough payroll taxes to keep benefits flowing to every retiree (Robert Reich, 4/11).
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 3 days ago
| Entity Name | Onv Care Of Nv, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639631344 PECOS PAC ID: 4385072917 Enrollment ID: O20200313002168 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
Forty years ago there were five workers for every retiree. Now there are three. Within a couple of decades, there will be only two workers per retiree. There's no way just two workers will be able or willing to pay enough payroll taxes to keep benefits flowing to every retiree (Robert Reich, 4/11).
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Archie Charles Perry Jr, MD 2800 E Desert Inn Rd Ste 100, Las Vegas, NV 89121-3609 Ph: (702) 731-1616 | Dr Archie Charles Perry Jr, MD 2800 E Desert Inn Rd Ste 100, Las Vegas, NV 89121-3609 Ph: (702) 731-1616 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
Forty years ago there were five workers for every retiree. Now there are three. Within a couple of decades, there will be only two workers per retiree. There's no way just two workers will be able or willing to pay enough payroll taxes to keep benefits flowing to every retiree (Robert Reich, 4/11).
Researchers at the Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical Research (Burnham) and the Centers for Disease Control and Prevention (CDC) have reported the identification of human monoclonal antibodies (mAb) that neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
› Verified 3 days ago
William Ralston Mcgee Ii, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9159 W Flamingo Rd Ste 100, Las Vegas, NV 89147 Phone: 024-855-8857 Fax: 888-593-7092 | |
Erik Noble Kubiak, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2231 West Charleston Blvd, Las Vegas, NV 89102 Phone: 702-383-2663 Fax: 702-383-2682 | |
Dr. Victor Hoang, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 620 Shadow Ln, Las Vegas, NV 89106 Phone: 702-388-8436 | |
Dr. Edward Ratcliffe Anderson Iii, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4750 W Oakey Blvd Ste 2b, Las Vegas, NV 89102 Phone: 702-579-3297 Fax: 702-796-2302 | |
Bradley Scott Baker, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7455 W Washington Ave, #160, Las Vegas, NV 89128 Phone: 702-878-0393 Fax: 702-933-0637 | |
Hugh S Selznick, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3006 S Maryland Pkwy, 570, Las Vegas, NV 89109 Phone: 702-777-2663 Fax: 702-777-0030 | |
Ronald W. Hillock, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7455 W Washington Ave, #160, Las Vegas, NV 89128 Phone: 702-878-0393 Fax: 702-258-5564 |